IFRX InflaRx N.V.

NASDAQ
$1.89

InflaRx N.V. (IFRX) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.8% since its last earnings release on August 6, 2026.

InflaRx N.V. Missed Consensus Estimates
Thursday, August 6, 2026 · 7:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 7:30 AM ET
Earnings Whisper
-
vs ($0.07)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.14

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About InflaRx N.V.

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.